Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 33 A 74
2. A 74, 33
3. Atracurium
4. Atracurium Besilate
5. Atracurium Dibesylate
6. Besilate, Atracurium
7. Bw 33a
8. Bw-33a
9. Bw33a
10. Relatrac
11. Tracrium
1. 64228-81-5
2. Atracurium Besilate
3. Tracrium
4. Atracurium (besylate)
5. Bw-33a
6. Atracurium Dibesylate
7. Atracurii Besilas
8. Besilate D'atracurium
9. Besilato De Atracurio
10. Bw 33a
11. Chebi:2915
12. Benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate
13. Nsc-760047
14. 2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) Benzenesulfonate
15. Atracurium Besilate (inn)
16. Atracurium Besilate [inn]
17. 51w89
18. Tracrium Preservative Free
19. Cis-atracurium Besylate
20. Atracurii Besilas [inn-latin]
21. Hydro-1h-isoquinolin-2-ium-2-yl]propanoate
22. Bw 33 A
23. Besilate D'atracurium [inn-french]
24. Einecs 264-743-4
25. Atracurium Besylate Preservative Free
26. Besilato De Atracurio [inn-spanish]
27. 33 A 74
28. Unii-40ax66p76p
29. Atracurium Besylate [usan:usp]
30. Ncgc00017127-01
31. Tracrium (tn)
32. Benzenesulfonate;5-[3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate
33. Benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-di
34. Cas-64228-81-5
35. Mfcd00797403
36. Dsstox_cid_2630
37. Atracurium Besylate (usp)
38. Dsstox_rid_76665
39. Dsstox_gsid_22630
40. Schembl41251
41. 2-(2-carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium Benzenesulfonate, Pentamethylene Ester
42. Pentamethylen Bis(3-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-2-methyl-2-isochinolyl)propionat) Bis(benzolsulfonat)
43. Chembl1200527
44. Dtxsid6022630
45. Hy-b0292a
46. 40ax66p76p
47. Hms1568a11
48. Hms2095a11
49. Hms3651c21
50. Hms3712a11
51. Hms3884g12
52. Pharmakon1600-01505872
53. Bcp22694
54. Bcp22909
55. Benzenesulfonate; 5-[3-[(1r,2r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1s,2s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propan
56. Tox21_110790
57. Nsc760047
58. S1832
59. Akos015895831
60. Ab07163
61. Atracurium Besylate, Mixture Of Isomers
62. Ccg-213566
63. Db00732
64. Nc00429
65. Nsc 760047
66. Ncgc00262598-01
67. Ncgc00262598-02
68. 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium] Dibenzenesulfonate
69. As-14131
70. Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, Dibenzenesulfonate
71. A2566
72. Ft-0657467
73. Ft-0659516
74. Sw197148-4
75. Atracurium Besylate, >=98% (hplc), Powder
76. D00758
77. Q165660
78. Sr-01000781272
79. Q-101018
80. Q-200864
81. Sr-01000781272-3
82. Atracurium Besilate Pound>>bw 33a Pound>>bw33a Pound>>bw-33a
83. Atracurium Besylate, European Pharmacopoeia (ep) Reference Standard
84. Atracurium Besylate, United States Pharmacopeia (usp) Reference Standard
85. Atracurium For Impurity F Identification, European Pharmacopoeia (ep) Reference Standard
86. Atracurium For Peak Identification, European Pharmacopoeia (ep) Reference Standard
87. 2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)benzenesulfonate
88. 2,2'-(3,3'-(pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium) Benzenesulfonate
89. 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium Benzenesulfonate
90. 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
91. 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-{[3,4-bis(methyloxy)phenyl]methyl}-2-methyl-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinolinium] Bisbenzenesulfonate
| Molecular Weight | 1243.5 g/mol |
|---|---|
| Molecular Formula | C65H82N2O18S2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 18 |
| Rotatable Bond Count | 26 |
| Exact Mass | 1242.50040612 g/mol |
| Monoisotopic Mass | 1242.50040612 g/mol |
| Topological Polar Surface Area | 258 Ų |
| Heavy Atom Count | 87 |
| Formal Charge | 0 |
| Complexity | 1560 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 4 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 4 | |
|---|---|
| Drug Name | Atracurium besylate |
| Drug Label | Atracurium besylate is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. Atracurium besylate is designated as 2-(2-Carboxyethyl)-1, 2, 3, 4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium b... |
| Active Ingredient | Atracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Hospira; Sagent Pharms; Eurohlth Intl |
| 2 of 4 | |
|---|---|
| Drug Name | Atracurium besylate preservative free |
| Active Ingredient | Atracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Hospira; Sagent Pharms; Eurohlth Intl |
| 3 of 4 | |
|---|---|
| Drug Name | Atracurium besylate |
| Drug Label | Atracurium besylate is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. Atracurium besylate is designated as 2-(2-Carboxyethyl)-1, 2, 3, 4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium b... |
| Active Ingredient | Atracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Hospira; Sagent Pharms; Eurohlth Intl |
| 4 of 4 | |
|---|---|
| Drug Name | Atracurium besylate preservative free |
| Active Ingredient | Atracurium besylate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10mg/ml |
| Market Status | Prescription |
| Company | Hospira; Sagent Pharms; Eurohlth Intl |
For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Neuromuscular Nondepolarizing Agents
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)
Nicotinic Antagonists
Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)
The elimination half-life is approximately 20 minutes.
Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Parenteral
Solubilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
